Cancer Res
Characterization of Imlunestrant as an Oral, Brain-Penetrant SERD
Bhagwat SV, Mur C, Vandekopple M, et al
Imlunestrant is a next-generation, brain-penetrant oral ERα degrader. Imlunestrant has potent activity in ESR1 wild-type and ESR1-mutant breast cancer, enhances combination activity with standard-of-care agents, and inhibits growth of ER+ intracranial tumors.
Previous Article
- • Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
- • Imlunestrant Monotherapy: Phase 1a/1b EMBER Study
- • Characterization of Imlunestrant as an Oral, Brain-Penetrant SERD
- • Pharmacodynamics from EMBER-2
- • Imlunestrant: First Approval
- • Imlunestrant Overcomes ESR1 Mutant Resistance in ER-Positive Breast Cancer
- • ESR1 Mutations in Breast Cancer
